Bronchodilator therapy in COPD: Current thinking and new paradigms

04 Aug 2017
Bronchodilator therapy in COPD: Current thinking and new paradigms
Prof Dr. Klaus F. Rabe

Inhaled bronchodilators is key to symptom control in COPD, says the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 guidelines. In fact, long-acting bronchodilators are the therapy-of-choice; and for COPD patients with persistent symptoms, dual bronchodilator therapy is now the way forward. Tiotropium/Olodaterol (Spiolto® Respimat®, Boehringer Inghelheim) is the latest dual bronchodilator therapy available in Malaysia. Please look out for our upcoming Symposium Highlight article on Spiolto Respimat to find out what Professor Klaus F. Rabe has to say about this particular combination. 

Related MIMS Drugs

Editor's Recommendations